Supplementary Figure Legends from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1: Nomenclature of oncolytic HSV-1 and their genetics; Supplementary Figure 1: RUX does not impair 67C-4 MPNST tumor cell growth; Supplementary Figure 2: Viral replication is integral to RUX/C134 anti-tumor effect.; Supplementary Figure 3: Combined RUX and C134 treatment effect on the infiltrating lymphocytes; Supplementary Figure 4: Virus treatment increases CD8 activation in the periphery (D3) and combination therapy maintains the activation (D5); Supplementary Figure 5: 67C-4 tumor cells express EphA2 and control peptide doesn't induce CD8 T cell activation.
Authors: Mohammed G. Ghonime, Kevin A. Cassady
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362618893